Literature DB >> 26125953

Positively Charged Chitosan and N-Trimethyl Chitosan Inhibit Aβ40 Fibrillogenesis.

Haiyang Liu, Bimlesh Ojha, Clifford Morris, Mengting Jiang, Ewa P Wojcikiewicz, Praveen P N Rao1, Deguo Du.   

Abstract

Amyloid fibrils, formed by aggregation of improperly folded or intrinsically disordered proteins, are closely related with the pathology of a wide range of neurodegenerative diseases. Hence, there is a great deal of interest in developing molecules that can bind and inhibit amyloid formation. In this regard, we have investigated the effect of two positively charged polysaccharides, chitosan (CHT) and its quarternary derivative N-trimethyl chitosan chloride (TMC), on the aggregation of Aβ40 peptide. Our aggregation kinetics and atomic force microscopy (AFM) studies show that both CHT and TMC exhibit a concentration-dependent inhibiting activity on Aβ40 fibrillogenesis. Systematic pH-dependent studies demonstrate that the attractive electrostatic interactions between the positively charged moieties in CHT/TMC and the negatively charged residues in Aβ40 play a key role in this inhibiting activity. The stronger inhibiting activity of TMC than CHT further suggests the importance of charge density of the polymer chain in interacting with Aβ40 and blocking the fibril formation. The possible interactions between CHT/TMC and Aβ40 are also revealed at the atomic level by molecular docking simulation, showing that the Aβ40 monomer could be primarily stabilized by electrostatic interactions with charged amines of CHT and quaternary amines of TMC, respectively. Binding of CHT/TMC on the central hydrophobic core region of Aβ40 peptide may be responsible for blocking the propagation of the nucleus to form fibrillar structures. These results suggest that incorporation of sugar units such as d-glucosamine and N-trimethyl-d-glucosamine into polymer structural template may serve as a new strategy for designing novel antiamyloid molecules.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26125953     DOI: 10.1021/acs.biomac.5b00603

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  7 in total

1.  Gold Nanoparticles as a Probe for Amyloid-β Oligomer and Amyloid Formation.

Authors:  Esmail A Elbassal; Clifford Morris; Thomas W Kent; Richard Lantz; Bimlesh Ojha; Ewa P Wojcikiewicz; Deguo Du
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2017-08-22       Impact factor: 4.126

Review 2.  Chitosan Nanoparticles in Atherosclerosis-Development to Preclinical Testing.

Authors:  Pornsak Sriamornsak; Crispin R Dass
Journal:  Pharmaceutics       Date:  2022-04-25       Impact factor: 6.525

3.  Suppression of amyloid fibrils using the GroEL apical domain.

Authors:  Bimlesh Ojha; Naoya Fukui; Kunihiro Hongo; Tomohiro Mizobata; Yasushi Kawata
Journal:  Sci Rep       Date:  2016-08-04       Impact factor: 4.379

Review 4.  Chitosan: A Natural Biopolymer with a Wide and Varied Range of Applications.

Authors:  Carmen P Jiménez-Gómez; Juan Antonio Cecilia
Journal:  Molecules       Date:  2020-09-01       Impact factor: 4.411

5.  Mucin-Type O-Glycosylation Proximal to β-Secretase Cleavage Site Affects APP Processing and Aggregation Fate.

Authors:  YashoNandini Singh; Deepika Regmi; David Ormaza; Ramya Ayyalasomayajula; Nancy Vela; Gustavo Mundim; Deguo Du; Dmitriy Minond; Maré Cudic
Journal:  Front Chem       Date:  2022-04-08       Impact factor: 5.545

Review 6.  Nanomedicines in the Management of Alzheimer's Disease: Current View and Future Prospects.

Authors:  Hitesh Chopra; Shabana Bibi; Inderbir Singh; Mohammad Amjad Kamal; Fahadul Islam; Fahad A Alhumaydhi; Talha Bin Emran; Simona Cavalu
Journal:  Front Aging Neurosci       Date:  2022-07-08       Impact factor: 5.702

Review 7.  Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases.

Authors:  Manel Dhahri; Mawadda Alghrably; Hamdoon A Mohammed; Syed Lal Badshah; Noreen Noreen; Fouzi Mouffouk; Saleh Rayyan; Kamal A Qureshi; Danish Mahmood; Joanna Izabela Lachowicz; Mariusz Jaremko; Abdul-Hamid Emwas
Journal:  Pharmaceutics       Date:  2021-12-21       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.